SYK allelic loss and the role of Syk-regulated genes in breast cancer survival

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Blancato, Jan ^a   Graves, Ashley ^a   Rashidi, Banafsheh ^b,g   Moroni, Maria ^c   Tchobe, Leopold ^a,d   Ozdemirli, Metin ^b   Kallakury, Bhaskar ^b   Makambi, Kepher H ^b   Marian, Catalin ^e,f   Mueller, Susette C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g Affiliated Pathologists Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTEIN KINASE SYK;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CELL INFILTRATION; CELL LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DNA METHYLATION; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; GENOME ANALYSIS; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; INTRADUCTAL CARCINOMA; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SYK GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME MAPPING; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; NEOPLASM INVASIVENESS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84895513082     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087610     Document Type: Article

References (85)

1. Mocsai A, Ruland J, Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10: 387-402.
2. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, et al. (2000) The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406: 742-747.
3. Sung YM, Xu X, Sun J, Mueller D, Sentissi K, et al. (2009) Tumor Suppressor Function of Syk in Human MCF10A In Vitro and Normal Mouse Mammary Epithelium In Vivo. PLoS ONE 4: e7445.
4. Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, et al. (2004) Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 64: 7346-7354. (Pubitemid 39372073)
5. Coopman PJ, Mueller SC (2006) The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Letters 241: 159-173. (Pubitemid 44163045)
6. Yuan Y, Mendez R, Sahin A, Dai JL (2001) Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 61: 5558-5561. (Pubitemid 32694942)
7. Yuan Y, Liu H, Sahin A, Dai JL (2005) Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113: 654-659. (Pubitemid 40038744)
8. Layton T, Stalens C, Gunderson F, Goodison S, Silletti S (2009) Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol 175: 2625-2636.
9. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 11187-11193. (Pubitemid 46009946)
10. Dong SW, Ma L, Xu N, Yan HQ, Liu HY, et al. (2011) Research on the reactivation of Syk expression caused by the inhibition of DNA promoter methylation in the lung cancer. Neoplasma 58: 89-95.
11. Ogane S, Onda T, Takano N, Yajima T, Uchiyama T, et al. (2009) Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. Int J Cancer 124: 2651-2657.
12. Lee HS, Kim BH, Cho NY, Yoo EJ, Choi M, et al. (2009) Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res 15: 812-820.
13. Ma L, Dong S, Zhang P, Xu N, Yan H, et al. (2010) The relationship between methylation of the Syk gene in the promoter region and the genesis of lung cancer. Clin Lab 56: 407-416.
14. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, et al. (2007) DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 58: 220-230. (Pubitemid 47513257)
15. Kunze E, Wendt M, Schlott T (2006) Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int J Mol Med 18: 547-557.
16. Al Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP (2010) Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg 252: 1037-1043.
17. Inayat U, Kayani MA, Faryal R (2012) Sporadic mutations and expression analysis of spleen tyrosine kinase gene in breast cancer: a preliminary report. Pol J Pathol 63: 106-111.
18. Kanwal S, Kayani MA, Faryal R (2012) Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5′UTR. Mol Biol Rep 39: 8345-8351.
19. Minobe K, Onda M, Iida A, Kasumi F, Sakamoto G, et al (1998) Allelic loss on chromosome 9q is associated with lymph node metastasis of primary breast cancer. Jpn J Cancer Res 89: 916-922. (Pubitemid 28486817)
20. Cohen AL, Ward JH (2010) Risk reduction strategies for ductal carcinoma in situ. J Natl Compr Canc Netw 8: 1211-1217.
21. Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96: 906-920. (Pubitemid 38868137)
22. Jenkins RB, Qian J, Lieber MM, Bostwick DG (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57: 524-531. (Pubitemid 27081674)
23. Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, et al. (2011) Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med 13: 667-675.
24. Tennis M, Krishnan S, Bonner M, Ambrosone CB, Vena JE, et al. (2006) p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev 15: 80-85.
25. Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2: 2265-2275. (Pubitemid 351575045)
26. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: 11.
27. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
28. Cancer Genome Atlas Network. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
29. Reva B, Antipin Y, Sander C (2007) Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol 8: R232.
30. Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39: e118.
31. Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL (2009) Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7: 634-644.
32. Neuhaus B, Buhren S, Bock B, Alves F, Vogel WF, et al. (2011) Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors. Cell Mol Life Sci 68: 3757-3770.
33. Mahabeleshwar GH, Kundu GC (2003) Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem 278: 6209-6221. (Pubitemid 36800876)
34. Larive RM, Urbach S, Poncet J, Jouin P, Mascre G, et al. (2009) Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene 28: 2337-2347.
35. Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, et al. (2009) Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res 69: 2748-2756.
36. Maruyama S, Kurosaki T, Sada K, Yamanashi Y, Yamamoto T, et al. (1996) Physical and functional association of cortactin with Syk in human leukemic cell line K562. Journal of Biological Chemistry 271: 6631-6635. (Pubitemid 26104090)
37. Helwani FM, Kovacs EM, Paterson AD, Verma S, Ali RG, et al. (2004) Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol 164: 899-910
38. van Rossum AG, Moolenaar WH, Schuuring E (2006) Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 312: 1658-1670.
39. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29. (Pubitemid 30257031)
40. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med %19;347: 1999-2009.
41. Huderson BP, Duplessis TT, Williams CC, Seger HC, Marsden CG, et al. (2012) Stable inhibition of specific estrogen receptor alpha (ERalpha) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Endocrinology 153: 4144-4159.
42. Mueller SC, Artym VV, Kelly T (2008) Invadopodia: Interface for Invasion. In: Dylan E, Hoyer-Hansen G, Blasi F, Sloane BF, editors. The Cancer Degradome - Proteases in Cancer Biology. New York: Springer. pp. 403-432.
43. Courtneidge SA (2012) Cell migration and invasion in human disease: the Tks adaptor proteins. Biochem Soc Trans 40: 129-132.
44. Destaing O, Block MR, Planus E, Albiges-Rizo C (2011) Invadosome regulation by adhesion signaling. Curr Opin Cell Biol 23: 597-606.
45. Linder S (2007) The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 17: 107-117.
46. Linder S, Wiesner C, Himmel M (2011) Degrading devices: invadosomes in proteolytic cell invasion. Annu Rev Cell Dev Biol 27: 185-211.
47. Machesky LM, Li A (2010) Fascin: Invasive filopodia promoting metastasis. Commun Integr Biol 3: 263-270.
48. Poincloux R, Lizarraga F, Chavrier P (2009) Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 122: 3015-3024.
49. Sibony-Benyamini H, Gil-Henn H (2012) Invadopodia: the leading force. Eur J Cell Biol 91: 896-901.
50. Struckhoff AP, Rana MK, Worthylake RA (2011) RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 16:1915-26.: 1915-1926.
51. Stylli SS, Kaye AH, Lock P (2008) Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci 15: 725-737.
52. Yamaguchi H (2012) Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol 91: 902-907.
53. Ruschel A, Ullrich A (2004) Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. Cell Signal 16: 1249-1261. (Pubitemid 39165453)
54. Destaing O, Block MR, Planus E, Albiges-Rizo C (2011) Invadosome regulation by adhesion signaling. Curr Opin Cell Biol 23: 597-606.
55. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609. (Pubitemid 28034534)
56. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, et al. (2003) Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A 100: 13298-13302. (Pubitemid 37444736)
57. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, et al. (2003) The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem 278: 16844-16851. (Pubitemid 36799554)
58. Zhong JL, Poghosyan Z, Pennington CJ, Scott X, Handsley MM, et al. (2008) Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol Cancer Res 6: 383-394. (Pubitemid 351416529)
59. Ortiz RM, Karkkainen I, Huovila AP (2004) Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells. Genes Chromosomes Cancer 41: 366-378. (Pubitemid 39488495)
60. Aloisi AL, Bucci C (2013) Rab GTPases-cargo direct interactions: fine modulators of intracellular trafficking. Histol Histopathol 28: 839-849.
61. Mitra S, Cheng KW, Mills GB (2012) Rab25 in cancer: a brief update. Biochem Soc Trans 40: 1404-1408.
62. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 22: 131-145.
63. Subramani D, Alahari SK (2010) Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer 9:312. doi: 10.1186/1476-4598-9-312.: 312-319.
64. Eva R, Dassie E, Caswell PT, Dick G, Ffrench-Constant C, et al. (2010) Rab11 and its effector Rab coupling protein contribute to the trafficking of beta 1 integrins during axon growth in adult dorsal root ganglion neurons and PC12 cells. J Neurosci 30: 11654-11669.
65. Conklin MW, Ada-Nguema A, Parsons M, Riching KM, Keely PJ (2010) R-Ras regulates beta1-integrin trafficking via effects on membrane ruffling and endocytosis. BMC Cell Biol 11:14. doi: 10.1186/1471-2121-11-14.: 14-11.
66. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
67. Mills GB, Jurisica I, Yarden Y, Norman JC (2009) Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest 119: 2123-2127.
68. Chia WJ, Tang BL (2009) Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 1795: 110-116.
69. Tang BL, Ng EL (2009) Rabs and cancer cell motility. Cell Motil Cytoskeleton 66: 365-370.
70. Mosesson Y, Mills GB, Yarden Y (2008) Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8: 835-850.
71. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, et al. (2008) Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 183: 143-155.
72. Sandilands E, Frame MC (2008) Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol 18: 322-329.
73. Nishimura N, Sasaki T (2008) Regulation of epithelial cell adhesion and repulsion: role of endocytic recycling. J Med Invest 55: 9-16. (Pubitemid 351643588)
74. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, et al. (2007) Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13: 496-510. (Pubitemid 47514517)
75. Weaver V, Werb Z (2007) G'rab'bing the microenvironment for invasion. Dev Cell 13: 462-463. (Pubitemid 47500819)
76. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, et al. (2009) RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 119: 2171-2183.
77. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043.
78. Artym VV, Matsumoto K, Mueller SC, Yamada KM (2011) Dynamic membrane remodeling at invadopodia differentiates invadopodia from podosomes. Eur J Cell Biol 90: 172-180.
79. Weaver AM (2008) Cortactin in tumor invasiveness. Cancer Lett 265: 157-166.
80. Clark ES, Whigham AS, Yarbrough WG, Weaver AM (2007) Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 67: 4227-4235. (Pubitemid 46815069)
81. Schuuring E, Verhoeven E, Litvinov S, Michalides RJ (1993) The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-Src substrate and is located in cell-substratum contact sites. Mol Cell Biol 13: 2891-2898. (Pubitemid 23133960)
82. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, et al. (1991) Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. Cancer Res 51: 4028-4037.
83. Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, et al. (2010) Matrix metalloproteinases. Curr Med Chem 17: 3751-3768.
84. Murphy G, Nagase H (2008) Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308.
85. Kreiseder B, Orel L, Bujnow C, Buschek S, Pflueger M, et al. (2013) alpha-Catulin downregulates E-cadherin and promotes melanoma progression and invasion. Int J Cancer 132: 521-530.